64764-108-21 : NDC 2026 Code

64764-108-21 : Vedolizumab ( Entyvio Pen )

Additionally :

You can get information about “64764-108-21” NDC code in 64764-108-21 in HTML format

HTML | 64764-108-21 in TXT (Plain Text) format

TXT | 64764-108-21 in PDF (Portable Document Format)

PDF | 64764-108-21 in XML format

XML formats.

NDC Code : 64764-108-21 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "64764-108-21",
    "PackageDescription": "1 TRAY in 1 CARTON (64764-108-21)  / 1 SYRINGE in 1 TRAY (64764-108-20)  / .68 mL in 1 SYRINGE",
    "NDC11Code": "64764-0108-21",
    "ProductNDC": "64764-108",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Entyvio Pen",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Vedolizumab",
    "DosageFormName": "INJECTION, SOLUTION",
    "RouteName": "SUBCUTANEOUS",
    "StartMarketingDate": "20230927",
    "EndMarketingDate": null,
    "MarketingCategoryName": "BLA",
    "ApplicationNumber": "BLA761133",
    "LabelerName": "Takeda Pharmaceuticals America, Inc.",
    "SubstanceName": "VEDOLIZUMAB",
    "StrengthNumber": "108",
    "StrengthUnit": "mg/.68mL",
    "Pharm_Classes": "Integrin Receptor Antagonist [EPC], Integrin Receptor Antagonists [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-12-25",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20230927",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}